An Investigational Immuno-therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Patients With Solid Cancers That Are Advanced or Have Spread

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Patients must have at least 1 standard treatment regimen in the advanced, recurrent or
metastatic setting

- ECOG (Eastern Cooperative Oncology Group) 0-1

- Men and women 18 years old or older

- At least one measurable lesion at baseline by CT (computed tomography) or MRI
(magnetic resonance imaging) as per RECIST (Response Evaluation Criteria In Solid
Tumors) v1.1

- All subjects must have a fresh tumor biopsy

Exclusion Criteria:

- Known central nervous system metastases or central nervous system as the only source
of disease

- Concomitant malignancies

- Active known or suspected autoimmune disease

- Uncontrolled or significant cardiovascular disease

- Major surgery less than 4 weeks before the start of the study

- Patients with known allergies to egg products, neomycin, or tetanus toxoid

- Prior adverse reaction to tetanus toxoid-containing vaccines

Other protocol defined inclusion/exclusion criteria could apply